Phase II trial
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Phase II trial
Aug 26, 2024, 21:42 |
Blog
Tanja Obradovic: Interesting update at ESMO 2024 on cancer-induced cachexia as PhII trial of ponsegromab
Tanja Obradovic posted on LinkedIn: “Interesting update will come at ESMO 2024 on possible option…
Jul 20, 2024, 21:00 |
Blog
Nelson Dusetti: We are grateful to INCa for funding our project - NeoPREDICT
Nelson Dusetti shared a post on LinkedIn: . "We are grateful to INCa for funding…
Jun 29, 2024, 14:04 |
Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 10, 2024, 12:19 |
Insight
Results from the TRAP trial presented at ESTRO24
ESTRO shared on X/Twitter: "Results from the TRAP trial presented at ESTRO24: this phase-II trial explores…
Apr 15, 2024, 04:04 |
Blog
Amalya Sargsyan: Proud to see IMMONC spotlighted in ASCO's latest policy statement on global equity in clinical trials
Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, posted on LinkedIn: "Extremely proud to…
All:
5
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube